- Home
- RIGL vs AMBC Comparison
RIGL vs AMBC Comparison
Compare RIGL & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- AMBC
- Stock Information
- Founded
- RIGL 1996
- AMBC 1991
- Country
- RIGL United States
- AMBC United States
- Employees
- RIGL N/A
- AMBC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- AMBC Property-Casualty Insurers
- Sector
- RIGL Health Care
- AMBC Finance
- Exchange
- RIGL Nasdaq
- AMBC Nasdaq
- Market Cap
- RIGL 486.4M
- AMBC 544.2M
- IPO Year
- RIGL 2000
- AMBC 1991
- Fundamental
- Price
- RIGL $20.09
- AMBC $11.59
- Analyst Decision
- RIGL Buy
- AMBC Strong Buy
- Analyst Count
- RIGL 5
- AMBC 2
- Target Price
- RIGL $34.80
- AMBC $17.00
- AVG Volume (30 Days)
- RIGL 223.6K
- AMBC 337.3K
- Earning Date
- RIGL 03-04-2025
- AMBC 02-26-2025
- Dividend Yield
- RIGL N/A
- AMBC N/A
- EPS Growth
- RIGL N/A
- AMBC N/A
- EPS
- RIGL 0.22
- AMBC N/A
- Revenue
- RIGL $157,374,000.00
- AMBC $398,000,000.00
- Revenue This Year
- RIGL $51.34
- AMBC N/A
- Revenue Next Year
- RIGL $15.75
- AMBC N/A
- P/E Ratio
- RIGL $91.32
- AMBC N/A
- Revenue Growth
- RIGL 21.65
- AMBC 22.46
- 52 Week Low
- RIGL $7.48
- AMBC $10.12
- 52 Week High
- RIGL $29.82
- AMBC $18.45
- Technical
- Relative Strength Index (RSI)
- RIGL 45.75
- AMBC 48.88
- Support Level
- RIGL $20.00
- AMBC $11.25
- Resistance Level
- RIGL $21.93
- AMBC $11.99
- Average True Range (ATR)
- RIGL 1.30
- AMBC 0.32
- MACD
- RIGL -0.27
- AMBC 0.02
- Stochastic Oscillator
- RIGL 2.01
- AMBC 45.95
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.